RELATED CONTENT
June 14, 2022 — Munir Ghesani, MD, FACNM, FACR, chief of nuclear medicine and molecular imaging at Mount Sinai Health ...
June 14, 2022 
April 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear ...
April 13, 2022 
April 11, 2022 — A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre ...
April 11, 2022 
March 23, 2022 — With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical ...
March 23, 2022 
March 23, 2022 — A significant number of COVID-19 neurological complications— such as fatigue, headache, and cognitive ...
March 23, 2022 
March 16, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the Da ...
March 16, 2022 
January 17, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) issued a statement on Jan. 14 regarding ...
January 17, 2022 
August 4, 2021 — The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient ...
August 04, 2021 I recently attended the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in San Diego. This year’s meeting included a celebration of the 40th anniversary of FDG, a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET) that has had a pervasive impact on molecular imaging. At the opening plenary session, the Henry Wagner Lecture was given by Joanna Fowler, Ph.D., Brookhaven National Laboratory, on “Designing and Synthesizing FDG for the First Human Studies in 1976.” Signage throughout the convention center featured FDG pioneers and quotes on FDG by past presidents.
July 06, 2016